Long-Term GLP-1 9 Side Effects: What We Know Now vs What People Fear (Updated for 2026)
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Updated: September 2026
The longest human trial data on these medications runs about three to four years, and in that window the picture has moved in two directions at once. Regulators dropped one warning entirely in January 2026 after reviewing more than two million users. They added a new one for a rare eye condition in Europe and the UK, which the US label still doesn't carry. Here's what has actually been established, and what's still a worry rather than a finding.
Who This Helps
This is for you if you're on a GLP-1 and wondering what the years ahead look like, or if a headline has you considering stopping. If you're weighing that specifically, our piece on what happens after you stop covers that separately.
The suicidality warning was removed completely
On January 13, 2026 the FDA asked manufacturers to take the suicidal ideation warning off the labels of Saxenda, Wegovy and Zepbound. The agency said the action "follows a comprehensive FDA review that found no increased risk of SI/B [suicidal intent/behavior]" (FDA).
The review behind it was large. A meta-analysis of 91 placebo-controlled trials covering 107,910 patients "did not show an increased risk for SI/B or for other relevant psychiatric adverse events," and a Sentinel system cohort of 2,243,138 users "did not find an increased risk of intentional self-harm."
Mood changes on these medications can absolutely happen, it just means that there were no findings that the changes happened because of the medication. The specific fear that the drug causes suicidal thinking didn't hold up when tested at scale, and the label now reflects that, but you might still hear that as a side effect when talking with other people who aren’t as up-to-date.
A rare eye condition was added, and the US label lags
European regulators concluded in June 2025 that NAION, a form of sudden vision loss, is "a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide)" (European Medicines Agency). They put the scale at "approximately one additional case of NAION per 10,000 person-years of treatment." The UK regulator reached the same conclusion in February 2026, while noting "there was conflicting evidence in the literature" (MHRA).
We searched the current US Wegovy prescribing information for any mention of NAION or optic neuropathy and found none (Wegovy prescribing information). So a European patient and an American patient taking the same molecule are reading different safety information right now.
The eye societies have not told anyone to stop or change prescriptions because of this, but not because they aren’t taking it seriously. The American Academy of Ophthalmology and the neuro-ophthalmology society said together that "a review of the available data has not established that semaglutide causes NAION, only a potential link between the two" (American Academy of Ophthalmology). We cover the absolute numbers and the litigation behind the headlines in our full breakdown of the vision loss claims.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Pancreatitis looks better than the label suggests
Pancreatitis is one of the most common worries people bring us, and the accumulated evidence has been reassuring rather than alarming. In the Wegovy trials, adjudicated acute pancreatitis occurred in "4 WEGOVY-treated patients (0.2 cases per 100 patient years)" against one on placebo (Wegovy prescribing information). A 2026 pooled analysis across 31 trials and 40,274 patients found an odds ratio of 0.99 with a confidence interval spanning 0.67 to 1.45, which is to say no detectable increase. That analysis is a preprint and has not completed peer review, so treat it as the current best estimate rather than the final word.
The instruction on the labels has not changed and still matters: if pancreatitis is suspected, stop the medication, and don't restart it if pancreatitis is confirmed (Zepbound prescribing information).
What has actually held up over time
- Gallbladder problems are real and modest. In the Wegovy trials, gallstones occurred in 1.6% against 0.7% on placebo, and gallbladder inflammation in 0.6% against 0.2% (Wegovy prescribing information). A trial meta-analysis put the relative risk at 1.37, higher in weight-loss trials than in diabetes trials (JAMA Internal Medicine).
- Digestive effects remain the main story. A cohort study found higher rates of gastroparesis and bowel obstruction in people using these medications for weight loss (JAMA). For most people these settle, and our piece on what week six looks like covers the ordinary version.
- Kidney injury traces back to dehydration. Both labels describe acute kidney injury occurring mostly in people who became dehydrated through vomiting or diarrhea, rather than through any direct effect on the kidney.
- The thyroid boxed warning is unchanged. It still says it is unknown whether these drugs cause thyroid C-cell tumors in humans, because the human relevance of the rodent findings has not been determined. Unknown after years of use isn't the same as established.
- Muscle loss is measured, functional harm is not. Body composition studies show lean mass falls alongside fat. No peer-reviewed study has yet demonstrated resulting strength loss, falls or frailty, so treat that as an open question rather than a documented outcome.
How long the evidence actually runs
This is the honest limit on everything above. For semaglutide, the longest randomized evidence is the SELECT cardiovascular trial, with a mean follow-up of about 3.3 years (New England Journal of Medicine). For tirzepatide, the longest completed dataset runs to roughly three and a half years. Nobody has published a decade of randomized human data on either, because it doesn't exist yet.
So, the research goes both ways and isn’t entirely conclusive yet. Genuine long-term reassurance isn't available, and neither are the frightening long-term claims circulating online. Anyone speaking confidently about year ten is speculating.
Final Takeaway
At the end of the day, the real conversation you should be having on likelihood of risk is with your clinician. One widely repeated fear was tested properly and dropped from the labels. One rare risk was confirmed and added, though not yet in the United States. Everything else looks much as it did, with digestive and gallbladder effects still the realistic things to plan around. If you're on one of these medications, the useful posture is neither dread nor dismissal. Know the handful of symptoms that warrant a call, keep your check-ins, and don't trust anything claiming to know what happens after a decade. We will update this piece again as the evidence lengthens.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Do GLP-1 medications still carry a suicide warning?
No. In January 2026 the FDA asked manufacturers to remove that warning from Saxenda, Wegovy and Zepbound after a review covering 91 trials and a database of more than two million users found no increased risk.
Is the vision loss risk a reason to stop?
The eye societies say no, and specifically declined to recommend blanket discontinuation. European regulators describe the condition as very rare, affecting up to 1 in 10,000 people. Sudden vision loss in one eye is a reason to seek urgent care the same day, whether or not you take a GLP-1.
How many years of safety data exist?
About three to four years of randomized trial evidence for both semaglutide and tirzepatide. That is the ceiling on what anyone can claim in either direction about long-term effects.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
Worried about GLP-1 side effects like stomach paralysis or “Ozempic face”? This guide debunks myths with real research and clear answers.
Worried about GLP-1 side effects? Learn what’s common, how often it happens, and when symptoms usually start.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.